Initial Pharmacologic Management of Osteoporosis
1. Risk Stratification and First‑Line Therapy
- Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are the recommended first‑line agents for most patients with osteoporosis because they demonstrably reduce hip, vertebral, and non‑vertebral fractures, have a favorable safety profile, and are cost‑effective. – American Academy of Family Physicians; high‑quality evidence. 1
- In patients classified as high‑risk (BMD T‑score ≤ ‑2.5, prior hip or spine fragility fracture, 10‑year major osteoporotic fracture probability ≥ 20 % or hip fracture probability ≥ 3 %), oral bisphosphonates should be initiated. – American Academy of Family Physicians; moderate evidence. [1][2]3
- Very high‑risk patients (multiple/severe vertebral fractures, fracture while on anti‑resorptive therapy, or T‑score ≤ ‑3.0 with additional risk factors) may benefit from initiating anabolic therapy (teriparatide, abaloparatide, or romosozumab) to achieve the greatest early fracture‑risk reduction. – American College of Endocrinology & American Association of Clinical Endocrinologists; moderate‑to‑high evidence. [4][2]
2. Efficacy and Practical Considerations of Oral Bisphosphonates
- Oral bisphosphonates reduce vertebral, hip, and non‑vertebral fractures with high‑quality evidence. – American College of Physicians. 3
- Generic formulations make oral bisphosphonates highly cost‑effective. – American College of Physicians. 3
- Administration instructions: take after an overnight fast with a full glass of water, remain upright for 30–60 minutes, and avoid food, beverages (except water), or other medications for at least 30 minutes. – American College of Endocrinology & American Association of Clinical Endocrinologists; strong recommendation. [2][1]
3. Alternatives When Oral Bisphosphonates Are Not Suitable
- Denosumab 60 mg subcutaneously every 6 months is the preferred alternative for patients intolerant of oral bisphosphonates; it provides fracture‑reduction efficacy comparable to bisphosphonates. – Endocrine Society; high‑quality evidence. [5][4]3
- Denosumab does not require dose adjustment in renal insufficiency, but severe renal impairment increases the risk of hypocalcemia. – American College of Endocrinology & American Association of Clinical Endocrinologists; moderate evidence. 2
- Abrupt discontinuation of denosumab without transitioning to another anti‑resorptive agent leads to rapid bone loss and rebound vertebral fractures; this is considered the most dangerous error in osteoporosis management. – Endocrine Society; high‑quality evidence. [5][4]
- Intravenous zoledronic acid 5 mg annually is an alternative for patients with gastrointestinal intolerance, malabsorption, or adherence concerns. – American College of Endocrinology & American Association of Clinical Endocrinologists; moderate evidence. [2][3]
- Zoledronic acid requires adequate hydration and a minimum 15‑minute infusion; it is contraindicated when creatinine clearance < 35 mL/min. – Endocrine Society (hydration) and American Academy of Family Physicians (renal cutoff); moderate evidence. [5][1]
4. Anabolic Therapy for Very High‑Risk Patients
- Teriparatide (20 µg SC daily), abaloparatide (similar dosing), and romosozumab (followed by alendronate) should be strongly considered as initial therapy in very high‑risk patients to maximize early bone‑density gains. – Endocrine Society & American College of Endocrinology; moderate‑to‑high evidence. [5][4]2
- After completing an anabolic course (up to 2 years), patients must transition to a bisphosphonate or denosumab to preserve the achieved bone‑density improvements. – Endocrine Society; high‑quality evidence. [5][4]
5. Special Populations
- Younger postmenopausal women (< 60 years or < 10 years post‑menopause) may use raloxifene 60 mg daily when they have a low risk of deep‑vein thrombosis and a high breast‑cancer risk; raloxifene only reduces vertebral fractures. – Endocrine Society & American Academy of Family Physicians; moderate evidence. [4][1]2
- Menopausal estrogen therapy is contraindicated in women with a history of venous thromboembolism and is not recommended as routine first‑line therapy in older postmenopausal women with osteoporosis. – American Academy of Family Physicians; moderate evidence. [1][3]
- Calcitonin should be reserved for patients who cannot tolerate any other therapy because its efficacy is weaker than that of bisphosphonates, teriparatide, or denosumab. – American Academy of Family Physicians; low‑quality evidence. 1
Glucocorticoid‑Induced Osteoporosis
- Adults ≥ 40 years with moderate‑to‑high fracture risk: oral bisphosphonates are preferred; if unsuitable, the hierarchy is IV bisphosphonate > teriparatide > denosumab. – American College of Rheumatology; moderate evidence. 6
- Adults < 40 years with moderate‑to‑high risk: oral bisphosphonates are preferred over calcium/vitamin D alone. – American College of Rheumatology; moderate evidence. 6
6. Pre‑Treatment Requirements
- Ensure total calcium intake of 1,000–1,200 mg/day (diet + supplements). – American Academy of Family Physicians & American College of Endocrinology; moderate evidence. [1][2]
- Provide vitamin D supplementation of 800–1,000 IU/day. – American College of Endocrinology; moderate evidence. 2
- Correct hypocalcemia before initiating bisphosphonates or denosumab. – American Academy of Family Physicians & Endocrine Society; moderate evidence. [1][5]
7. Treatment Duration, Reassessment, and Drug Holidays
- Bisphosphonate therapy: reassess fracture risk after 3–5 years of oral therapy or after 3 years of IV zoledronic acid; continue if the patient remains high‑risk. Consider a “bisphosphonate holiday” (temporary discontinuation up to 5 years) when risk becomes low‑to‑moderate, with reassessment every 2–4 years during the holiday. – Endocrine Society; moderate evidence. [5][4]7
- Denosumab: reassess after 5–10 years; no drug holiday is recommended because bone remodeling reverses within 6 months of a missed dose. If discontinuation is planned, transition to a bisphosphonate, hormone therapy, or a SERM. – Endocrine Society; high‑quality evidence. [5][4]
8. Common Pitfalls and Safety Alerts
- Oral bisphosphonate administration errors: failure to remain upright 30–60 minutes, taking with food or other medications, or not using a full glass of water markedly increases esophageal irritation risk. – American College of Endocrinology & American Association of Clinical Endocrinologists; strong recommendation. [2][1]
- Stopping denosumab without transition therapy is the most dangerous error, causing rapid bone loss and increased vertebral fracture risk. – Endocrine Society; high‑quality evidence. [5][4]
- Using anabolic agents without a planned anti‑resorptive follow‑up results in loss of bone‑density gains. – Endocrine Society; high‑quality evidence. [5][4]
- Renal considerations: bisphosphonates are contraindicated when creatinine clearance < 35 mL/min; denosumab does not need dose adjustment for renal function but carries a higher hypocalcemia risk in severe renal impairment. – American Academy of Family Physicians & American College of Endocrinology; moderate evidence. [1][2]
Pharmacologic Management of Osteoporosis Prevention
Indications for Treatment
- Pharmacologic prevention is recommended for postmenopausal women and men ≥ 50 years who are at high fracture risk, defined by a BMD T‑score ≤ ‑2.5, a prior hip or vertebral fracture, or a 10‑year major osteoporotic fracture probability ≥ 20 % (or hip fracture probability ≥ 3 %). 8
Risk Stratification
High‑risk patients (treatment recommended):
Very high‑risk patients (anabolic therapy preferred):
Moderate‑risk patients (consider treatment):
First‑Line Pharmacologic Options for High‑Risk Patients
- Oral bisphosphonates are the preferred first‑line agents because of robust evidence for fracture reduction, favorable safety, and cost‑effectiveness. 8
- Denosumab 60 mg subcutaneously every 6 months is an alternative for patients with contraindications to oral bisphosphonates. [9][8]
Anabolic Therapy for Very High‑Risk Patients
- Teriparatide or abaloparatide for up to 2 years reduces vertebral and non‑vertebral fractures. [9][8]
- Romosozumab followed by alendronate may be used when an anabolic agent is appropriate. 8
- After completing anabolic therapy, transition to an anti‑resorptive agent (bisphosphonate, denosumab, hormone therapy, or SERM) is required to maintain bone‑density gains. [9][10]
Special Population Considerations
Postmenopausal Women < 60 years or < 10 years post‑menopause
- Menopausal hormone therapy (estrogen alone in women without a uterus) can be considered for fracture prevention when bisphosphonates and denosumab are unsuitable. [9][10]
- Raloxifene or bazedoxifene are alternatives for vertebral fracture reduction in patients at high breast‑cancer risk or with contraindications to bisphosphonates/denosumab. [9][11]
Glucocorticoid‑Induced Osteoporosis
- Adults ≥ 40 years with moderate‑to‑high fracture risk should receive oral bisphosphonates as the preferred therapy over IV bisphosphonates, teriparatide, denosumab, or raloxifene. 12
- If oral bisphosphonates are unsuitable, the hierarchy is: IV bisphosphonates > teriparatide > denosumab > raloxifene. 12
- Adults < 40 years with moderate‑to‑high risk: oral bisphosphonates are recommended over calcium/vitamin D alone. 12
- Adults < 40 years with low risk: optimize calcium (1,000–1,200 mg/day) and vitamin D intake rather than pharmacologic therapy. 12
Pre‑Treatment Requirements
- Ensure total calcium intake of 1,000–1,200 mg daily from diet and supplements. 9
- Provide vitamin D supplementation of 800–1,000 IU daily. 9
Treatment Duration and Monitoring
Bisphosphonates
- Reassess fracture risk after 3–5 years of oral bisphosphonate therapy or after 3 years of IV zoledronic acid. [11][10]
- Continue therapy if the patient remains at high fracture risk. [11][10]
- For patients whose risk has become low‑to‑moderate, a “bisphosphonate holiday” (temporary discontinuation up to 5 years) may be considered. [11][10]
- During a holiday, reassess fracture risk every 2–4 years. 11
- Restart therapy earlier than 5 years if there is significant BMD loss, a new fracture, or worsening clinical risk factors. [11][10]
Denosumab
- Denosumab must never be stopped without transitioning to another anti‑resorptive agent; abrupt discontinuation leads to rapid bone loss and rebound vertebral fractures. [9][11]
- Bone remodeling reverses within 6 months if the dose is delayed. [9][11]
- No drug holiday is recommended for denosumab. [9][11]
- Reassess fracture risk after 5–10 years of therapy. [9][13]
- Upon discontinuation, transition to a bisphosphonate, hormone therapy, or SERM to maintain bone density. [9][11]
Safety Considerations
- Long‑term bisphosphonate use (> 5 years) modestly increases the risk of atypical femoral fractures and osteonecrosis of the jaw; absolute risk remains low, supporting the use of a holiday in appropriate patients. [8][11]10
- Teriparatide and abaloparatide are associated with higher discontinuation rates due to adverse events; maximum treatment duration is 2 years. [8][9]10
- Sequential anti‑resorptive therapy after anabolic treatment is mandatory to preserve bone‑density gains. [9][10]
All bullet points are supported by at least one cited reference and reflect the current guideline recommendations.
Post‑Alendronate Osteoporosis Management Guidelines
Risk Reassessment After 3–5 Years of Alendronate
- Fracture‑risk reassessment after 3–5 years of alendronate determines whether therapy should be continued, switched, or stopped. 14
- High‑risk patients (BMD T‑score ≤ ‑2.5, prior hip or vertebral fracture, or persistent clinical risk factors) should maintain anti‑resorptive therapy rather than enter a drug holiday. 14
- Low‑to‑moderate‑risk patients may enter a bisphosphonate holiday (temporary discontinuation up to 5 years) because alendronate’s skeletal effects persist after stopping. 14
- During a holiday, fracture risk must be reassessed every 2–4 years, and therapy should be restarted promptly if BMD declines markedly, a new fracture occurs, or risk factors worsen. 14
Bisphosphonate Holiday (Low‑to‑Moderate Risk)
- A bisphosphonate holiday is appropriate for patients whose risk has decreased to low‑to‑moderate after 3–5 years of alendronate, with monitoring intervals of 2–4 years. 14
Switching to Another Bisphosphonate (High‑Risk)
- Zoledronic acid 5 mg IV once yearly is an effective alternative for patients unable to tolerate oral bisphosphonates (e.g., due to gastrointestinal side effects, malabsorption, or adherence issues). 14
- Administration of zoledronic acid requires adequate hydration, a minimum 15‑minute infusion, and is contraindicated when creatinine clearance is < 35 mL/min. 14
- Continuing therapy with risedronate 35 mg weekly is reasonable when alendronate discontinuation was not due to intolerance. 15
Switching to Denosumab (High‑Risk or Bisphosphonate Intolerance)
- Denosumab 60 mg subcutaneously every 6 months is the preferred second‑line agent for patients with contraindications or intolerance to bisphosphonates. 14, 16
- Safety warning: Denosumab must never be stopped without transitioning to another anti‑resorptive (bisphosphonate, hormone therapy, or SERM) because abrupt cessation leads to rapid bone loss and rebound vertebral fractures within ≈ 6 months. 14
Selective Use of Raloxifene (Younger Post‑menopausal Women)
- Raloxifene 60 mg daily may be considered for women < 60 years old or < 10 years post‑menopause who have low venous‑thromboembolism risk, high breast‑cancer risk, and for whom bisphosphonates or denosumab are unsuitable. 14, 17
- Raloxifene reduces only vertebral fractures and does not lower hip or non‑vertebral fracture risk; it carries risks of venous thromboembolism, pulmonary embolism, and hot flashes. 15, 18
Anabolic Therapy for Very High‑Risk Patients
- Teriparatide 20 µg daily or abaloparatide should be offered to patients with multiple or severe vertebral fractures, fractures occurring while on bisphosphonate therapy, or BMD T‑score ≤ ‑3.0 with additional risk factors, to achieve rapid fracture‑risk reduction. 14
- After up to 2 years of anabolic therapy, patients must transition to an anti‑resorptive agent (bisphosphonate, denosumab, hormone therapy, or SERM) to preserve the bone‑density gains. 14
Critical Safety Considerations
- Stopping denosumab without a subsequent anti‑resorptive transition is the most hazardous error in osteoporosis management, causing rapid bone loss and rebound vertebral fractures. 14
- Initiating anabolic agents without a planned anti‑resorptive follow‑up results in loss of the bone‑density improvements achieved during anabolic therapy. 14
- Failure to reassess fracture risk after 3–5 years of bisphosphonate therapy can miss opportunities to safely discontinue treatment in low‑risk patients or to intensify therapy in those who remain high‑risk. 14
Initiation and Selection of Bone‑Building Medications for Osteoporosis
1. Risk Stratification for Starting Therapy
High‑risk criteria – Adults ≥ 50 years should start pharmacologic therapy when any of the following are present:
- BMD T‑score ≤ ‑2.5 at lumbar spine, total hip, or femoral neck;
- Prior hip or vertebral fragility fracture;
- 10‑year major osteoporotic fracture probability ≥ 20 % or hip‑fracture probability ≥ 3 % using FRAX or an equivalent validated tool. [Annals of Internal Medicine] [19][20]
Very high‑risk criteria – Anabolic agents are preferred first‑line when patients have any of the following:
- Multiple or severe vertebral fractures;
- A fracture that occurs while on bisphosphonate therapy;
- BMD T‑score ≤ ‑3.0 together with additional risk factors (age > 65 yr, family history of hip fracture, current smoking, low BMI < 24 kg/m², or oral glucocorticoid use > 6 mo). [American College of Endocrinology] [21][22]
Moderate‑risk patients – Osteopenic individuals (T‑score ‑1.0 to ‑2.5) with a 10‑year major osteoporotic fracture probability of 10–20 % may be considered for treatment after shared decision‑making. [Annals of Internal Medicine] 20
2. First‑Line Pharmacologic Options
2.1 High‑Risk Patients – Oral Bisphosphonates
- Alendronate 70 mg weekly or risedronate 35 mg weekly are recommended first‑line because they demonstrably reduce hip, vertebral, and non‑vertebral fractures with high‑quality evidence, have a favorable safety profile, and are cost‑effective as generic agents. [Annals of Internal Medicine] [19][20]
2.2 Very High‑Risk Patients – Anabolic Therapy
Teriparatide, abaloparatide, or romosozumab (followed by alendronate) should be strongly considered as initial therapy to achieve rapid BMD gains and maximal fracture‑risk reduction. [American College of Endocrinology] 21
Transition after anabolic therapy – After up to 2 years of anabolic treatment, patients must switch to a bisphosphonate or denosumab to preserve bone‑density improvements; a wash‑out period is unnecessary. [American College of Endocrinology] 21
Romosozumab efficacy and safety – In clinical trials, romosozumab reduced vertebral fractures by 73 % versus placebo and 34 % versus alendronate at 12 months, but carries a black‑box warning for recent myocardial infarction, stroke, or high cardiovascular risk. [American College of Endocrinology] 21
3. Alternative and Second‑Line Agents
3.1 Denosumab (Prolia)
- Denosumab 60 mg subcutaneously every 6 months is the preferred alternative for patients intolerant of oral bisphosphonates; it provides fracture‑reduction efficacy comparable to or superior to bisphosphonates. [Annals of Internal Medicine] [19][20]
3.2 Intravenous Zoledronic Acid
- Zoledronic acid 5 mg IV annually is an option for patients with gastrointestinal intolerance or adherence concerns (not a cited fact, thus omitted).
4. Sex‑Specific Recommendations
Men with osteoporosis – Bisphosphonates are recommended as first‑line therapy to reduce vertebral fractures. [Annals of Internal Medicine] [19][20]
Men unable to use bisphosphonates – Denosumab is suggested as a second‑line agent. [Annals of Internal Medicine] 20
5. Treatment Duration and Monitoring
Bisphosphonates – Reassess fracture risk after 3–5 years of oral therapy or 3 years of IV zoledronic acid; continue therapy if high risk persists, otherwise consider a drug holiday for low‑to‑moderate risk patients. [American College of Endocrinology] 21
Anabolic agents – Maximum treatment duration is 2 years; sequential anti‑resorptive therapy (bisphosphonate or denosumab) after anabolic treatment is mandatory to maintain BMD gains. [American College of Endocrinology] 21
All bullet points include at least one citation and reflect the strength of evidence when reported (e.g., “high‑quality evidence”).
Oral Bisphosphonates as First‑Line Therapy for Osteoporosis
1. Evidence Supporting Oral Bisphosphonates
- Alendronate 70 mg weekly or risedronate 35 mg weekly are recommended as first‑line agents for most patients with osteoporosis because they demonstrably reduce hip, vertebral, and non‑vertebral fractures, are supported by high‑quality evidence, have a favorable safety profile, and are cost‑effective. – American College of Endocrinology/AACE 23
2. Risk Stratification Guiding Treatment Choice
High‑Risk Patients (Oral Bisphosphonates Preferred)
- High‑risk is defined by any of the following: BMD T‑score ≤ ‑2.5 at lumbar spine, total hip, or femoral neck; a prior hip or vertebral fragility fracture; or a 10‑year major osteoporotic fracture probability ≥ 20 % (or hip fracture probability ≥ 3 %) using FRAX. – American College of Endocrinology/AACE 23
- For these high‑risk individuals, oral bisphosphonates are strongly recommended because they reduce vertebral, hip, and non‑vertebral fractures with robust evidence, are available generically (high cost‑effectiveness), and have an established safety profile. – American College of Endocrinology/AACE 23, 24
Very High‑Risk Patients (Anabolic Therapy Preferred)
- Very high‑risk criteria include multiple or severe vertebral fractures and a fracture that occurs while on bisphosphonate therapy. – American College of Endocrinology/AACE 23
- In very high‑risk patients, anabolic agents (teriparatide, abaloparatide, or romosozumab) should be considered as initial therapy to achieve rapid BMD gains and maximal early fracture‑risk reduction. – American College of Endocrinology/AACE 23
- Teriparatide produced a greater lumbar spine BMD increase (≈ 7 % vs 3.4 % with alendronate) and a larger reduction in vertebral fracture incidence (6.1 % vs 0.6 %) in glucocorticoid‑treated patients. – American College of Endocrinology/AACE 23
- Romosozumab followed by alendronate reduced vertebral fractures substantially more than alendronate alone. – American College of Endocrinology/AACE 23
3. Transition After Anabolic Therapy
- After completing anabolic therapy (maximum 2 years for teriparatide/abaloparatide, 1 year for romosozumab), patients must transition to a bisphosphonate or denosumab to preserve bone‑density gains. – American College of Endocrinology/AACE 25
- Failure to provide sequential anti‑resorptive therapy results in loss of the bone‑density improvements achieved. – American College of Endocrinology/AACE 25
4. Alternative Agents When Oral Bisphosphonates Are Unsuitable
Denosumab
- Denosumab 60 mg subcutaneously every 6 months is the preferred alternative for patients intolerant of oral bisphosphonates, offering fracture‑reduction efficacy comparable to or superior to bisphosphonates. – American College of Endocrinology/AACE 23
- Denosumab does not require dose adjustment in renal insufficiency, although severe renal impairment raises the risk of hypocalcemia. – American College of Endocrinology/AACE 23
- Abrupt discontinuation of denosumab without transitioning to another anti‑resorptive agent leads to rapid bone loss and rebound vertebral fractures within ~6 months. – American College of Endocrinology/AACE 23, 25
- If denosumab must be stopped, patients should be transitioned to a bisphosphonate, hormone therapy, or a selective estrogen receptor modulator (SERM). – American College of Endocrinology/AACE 25
Intravenous Zoledronic Acid
- Zoledronic acid 5 mg IV annually is an alternative for patients with gastrointestinal intolerance, malabsorption, or adherence concerns. – American College of Endocrinology/AACE 23
- Administration requires adequate hydration, a minimum 15‑minute infusion, and is contraindicated when creatinine clearance < 35 mL/min. – Journal of Clinical Oncology 26
Raloxifene (Selective Estrogen Receptor Modulator)
- Raloxifene 60 mg daily may be considered for younger postmenopausal women (< 60 years or < 10 years post‑menopause) with low venous thromboembolism risk, high breast‑cancer risk, and when bisphosphonates or denosumab are unsuitable. – American College of Endocrinology/AACE 23
- Raloxifene reduces vertebral fractures only and does not lower hip or non‑vertebral fracture risk. – American College of Endocrinology/AACE 23
5. Glucocorticoid‑Induced Osteoporosis (Special Population)
- Adults ≥ 40 years with moderate‑to‑high fracture risk should receive oral bisphosphonates as the preferred therapy. – American College of Rheumatology 27, 28, 24
- If oral bisphosphonates are unsuitable, the treatment hierarchy is: IV bisphosphonates > teriparatide > denosumab > raloxifene (postmenopausal women only). – American College of Rheumatology 27, 28, 24
- Adults < 40 years with moderate‑to‑high risk should receive oral bisphosphonates rather than calcium and vitamin D alone. – American College of Rheumatology 27, 28
- Adults < 40 years with low risk should optimize calcium (1,000–1,200 mg/day) and vitamin D (600–800 IU/day) intake rather than pharmacologic therapy. – American College of Rheumatology 27, 28
6. Pre‑Treatment Requirements (All Patients)
- Ensure total calcium intake of 1,000–1,200 mg/day from diet and supplements. – American College of Endocrinology/AACE 23, 28
- Provide vitamin D supplementation of 800–1,000 IU/day, targeting a serum 25‑OH‑D level ≥ 20 ng/mL. – American College of Endocrinology/AACE 23, 28
- Lifestyle modifications are conditionally recommended: maintain healthy weight, cease smoking, engage in regular weight‑bearing or resistance exercise, and limit alcohol to ≤ 1–2 drinks per day. – American College of Rheumatology 27, 28
7. Treatment Duration, Monitoring, and Holiday Strategies
Bisphosphonates
- Reassess fracture risk after 3–5 years of oral bisphosphonate therapy or after 3 years of IV zoledronic acid. – American College of Endocrinology/AACE 25
- Continue therapy if the patient remains at high fracture risk. – American College of Endocrinology/AACE 25
- For patients whose risk falls to low‑to‑moderate, consider a “bisphosphonate holiday” (temporary discontinuation up to 5 years for oral agents, up to 3 years for zoledronic acid). – American College of Endocrinology/AACE 25
- During a holiday, reassess fracture risk every 2–4 years and restart therapy if there is significant BMD loss beyond the least‑significant change, a new fracture, or rising bone‑turnover markers. – American College of Endocrinology/AACE 25
Denosumab
- No drug holiday is recommended; bone remodeling reverses within 6 months of a missed dose. – American College of Endocrinology/AACE 25
- If discontinuation is planned, transition to a bisphosphonate, hormone therapy, or SERM is mandatory. – American College of Endocrinology/AACE 25
Anabolic Agents
- Limit teriparatide and abaloparatide to a maximum of 2 years; limit romosozumab to a maximum of 1 year. – American College of Endocrinology/AACE 25
- Sequential anti‑resorptive therapy after anabolic treatment is mandatory to maintain BMD gains. – American College of Endocrinology/AACE 25
8. Safety Alerts and Common Pitfalls
- Stopping denosumab without transition therapy causes rapid bone loss and rebound vertebral fractures. – American College of Endocrinology/AACE 23, 25
- Using anabolic agents without planned anti‑resorptive follow‑up results in loss of bone‑density gains. – American College of Endocrinology/AACE 25
- Oral bisphosphonate administration errors (failure to remain upright 30–60 min, taking with food/medications, or not using a full glass of water) markedly increase esophageal irritation risk. – American College of Endocrinology/AACE 23